About Biotangents
Biotangents is a Healthcare company based in Edinburgh (United Kingdom) founded in 2015. Veterinary diagnostics products are developed for bovine viral diarrhea testing. Biotangents has raised $5.62 million across 5 funding rounds from investors including Gov.uk, Scottish Enterprise and Eos. The company has 13 employees. Biotangents offers products and services including AmpliSpec LAB Mastitis and AmpliSpec LAB BVDV. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Reagents and Kits and Genomics. Its legal entity is BIOTANGENTS LIMITED.
Company details
Biotangents was founded in 2015 in Edinburgh, United Kingdom, within the biotechnology sector focused on veterinary diagnostics. Products are offered for detecting bovine viral diarrhea through RNA-specific sections, utilizing Moduleic Sensing technology. This approach employs modular target-amplifier-reporter constructs to create nucleic acid detectors for animal health applications, supporting diagnostics in the veterinary field.
- Headquarters Edinburgh, United Kingdom
- Employees 13
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website biotangents.co.uk
- Social LinkedIn
- Legal Name Biotangents Limited
- Date of Incorporation 21 Jan, 2015
- Jurisdiction PENICUIK, SCOTLAND
- Total Equity Funding$5.62M (USD)
in 5 rounds
- Latest Funding Round$2.9M (USD), Series A
Nov 2024
- InvestorsGov.uk
& 5 more
- Employee Count13
Products & Services of Biotangents
Biotangents offers a comprehensive portfolio of products and services, including AmpliSpec LAB Mastitis and AmpliSpec LAB BVDV.
Rapid identification of bovine mastitis pathogens in cattle samples.
Detection of Bovine Viral Diarrhoea virus in cattle for disease control.
Funding Insights of Biotangents
Biotangents has successfully raised a total of $5.62M across 5 strategic funding rounds. The most recent funding activity was a Series A round of $2.9 million completed in November 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $5.62M
- Total Rounds 5
- Last Round Series A — $2.9M
- Investors Count 6
All 5 funding rounds of Biotangents with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2024 | $2.9M | Series A | – | Eos Advisory | |
| May 2022 | $745,986 | Seed | – | Scottish Enterprise | |
| May 2022 | $1.99M | Debt – Conventional | – | – | |
| May 2019 | $1.97M | Seed | – | Kelvin Capital | |
| Jun 2017 | Seed | – | Kelvin Capital, Scottish Investment Bank | – |
6 investors in total: 6 institutional.
Investors in Biotangents
Biotangents has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Gov.uk, Scottish Enterprise and Eos.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investment in science and technology is managed by Eos. | 2014 | eos-advisory.com | St Andrews, Scotland | |
Private debt investment firm focused on SMEs | bbinv.co.uk | Sheffield, United Kingdom | ||
| kelvincapital.com | ||||
Business development and leadership training programs are offered to companies. | 1991 | scottish-enterprise.com | Glasgow, United Kingdom | |
Online government services and information are provided to users. | 1707 | gov.uk | London, United Kingdom | |
| scottish-enterprise.com/sib |
Investor details for Biotangents
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Biotangents
15 people are tracked at Biotangents (4 in leadership, 6 in board & advisors, 5 in team); the tracked headcount is 13.
| Name | Role | Group |
|---|---|---|
Jason Ioannidis | Head Of Product Development | Leadership |
Fiona Marshall | Chief Executive Officer | Leadership |
Ivonne Robledo | Head Of Operations | Leadership |
Pascoe Harvey | Head of Assay R&D | Leadership |
Richard Hammond | Non-Executive Director | Board & advisors |
Ian Hamilton | Chairman | Board & advisors |
Ole Kring | Non-Executive Director | Board & advisors |
Alan Hale | Non-Executive Director | Board & advisors |
David Glen | Corporate & Finance Advisor | Board & advisors |
Steve Howell | Investor Director | Board & advisors |
Stefania Meconcelli | Laboratory Manager | Team |
William Ho | Senior Research Scientist | Team |
Suzana Savvi | Senior Bioinformatician | Team |
Cheryl Chan | Lead R&d Scientist | Team |
Saloni Dua | Transfer To Manufacture Scientist | Team |
Complete people profiles for Biotangents
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Biotangents
3 dated milestones of Biotangents across 9 years, from founding to its latest funding, stage changes and deals.
- Founded Biotangents is founded.
- Funding First funding round.
- Funding Latest funding round, Series A, of $2.9M.
Top companies in Genomics & Gene Therapy Platforms
2 companies that operate in the same segment as Biotangents (Genomics & Gene Therapy Platforms) in United Kingdom, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Biotangents
Complete news archive for Biotangents
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Biotangents
Biotangents was founded in 2015 and raised its 1st funding round 2 years after it was founded.
Biotangents is headquartered in Edinburgh, United Kingdom. It is registered at Edinburgh, Scotland, United Kingdom.
Biotangents is a funded company, having raised a total of $5.62M across 5 funding rounds to date.
Biotangents has 13 employees.
Biotangents was founded in 2015 in Edinburgh, United Kingdom, within the biotechnology sector focused on veterinary diagnostics. Products are offered for detecting bovine viral diarrhea through RNA-specific sections, utilizing Moduleic Sensing technology. This approach employs modular target-amplifier-reporter constructs to create nucleic acid detectors for animal health applications, supporting diagnostics in the veterinary field.
Biotangents offers AmpliSpec LAB Mastitis and AmpliSpec LAB BVDV.
Biotangents has 6 investors. Key investors include Gov.uk, Scottish Enterprise, Eos, British Business Investments, and Kelvin Capital.
Biotangents operates through Biotangents Limited.